BRIEF published on 09/24/2024 at 23:05, 1 year 8 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 8 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 8 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 8 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 9 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 9 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 9 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 9 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 9 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
Published on 06/11/2026 at 00:51, 46 minutes ago Touchstone Exploration Announces Closing of the Fundraise and Notice of AGM
Published on 06/11/2026 at 00:30, 1 hour 7 minutes ago BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
Published on 06/10/2026 at 23:05, 2 hours 32 minutes ago Faraday Copper Announces Annual General Meeting Voting Results
Published on 06/10/2026 at 14:30, 11 hours 7 minutes ago Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives
Published on 06/10/2026 at 23:56, 1 hour 41 minutes ago EQS-Adhoc: HUGO BOSS AG: HUGO BOSS informs about unsolicited voluntary takeover offer by Frasers Group plc
Published on 06/10/2026 at 22:05, 3 hours 32 minutes ago Ridgewood Infrastructure Acquires Dauntless Air, Premier Provider of Emergency Management Infrastructure
Published on 06/10/2026 at 21:45, 3 hours 52 minutes ago EQS-Adhoc: MAHLE has successfully priced the issuance of additional EUR 200 million notes due 2032 and is launching a partial tender offer for its outstanding notes due 2028
Published on 06/10/2026 at 20:11, 5 hours 26 minutes ago EQS-Adhoc: EDAG Engineering Group AG: Board of Directors resolves on capital measures to strengthen capital base
Published on 06/10/2026 at 18:39, 6 hours 58 minutes ago EQS-Adhoc: Kontron AG: Ad hoc announcement / Ennoconn Corporation intends to launch a mandatory takeover offer to Kontron AG shareholders
Published on 06/10/2026 at 18:29, 7 hours 8 minutes ago ICADE – PR – OUTCOME OF THE COMBINED GENERAL MEETING HELD ON JUNE 10 2026
Published on 06/10/2026 at 17:40, 7 hours 57 minutes ago Report on share repurchases from 3 to 9 June 2026
Published on 06/10/2026 at 07:00, 18 hours 37 minutes ago Acceleration of Museum Studio's international expansion
Published on 06/09/2026 at 19:30, 1 day 6 hours ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
